Pulse Pressure and Outcome in Kidney Transplantation: Results From the Collaborative Transplant Study

Background. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) are important predictors of graft and patient survival in renal transplantation. Pulse pressure (PP), the difference between systolic and diastolic pressure, has been associated with cardiovascular and renal morbidity in nontransplant epidemiological studies and clinical trials. Methods. In this large retrospective analysis of prospectively collected data, transplant recipients from 1995 to 2015 were examined for patient and death-censored graft survival. Results. In 43 006 recipients, a higher 1-year PP was significantly associated with inferior 10-year patient and death-censored graft survival. In patients 60 years or older, SBP but not DBP was associated with 10-year survival, an effect that was pronounced in patients with a normal SBP of <140 mm Hg and an increased PP of 60 mm Hg or greater, highlighting the superior impact of PP on survival in elderly recipients. In recipients 60 years or older, higher PP was associated with increased mortality due to circulatory system diseases but not to infection or cancer. The combination of PP 60 mm Hg or greater and high SBP of 140 mm Hg or greater showed the strongest association with death-censored graft survival across all age groups. Conclusions. We found convincing evidence that PP 1-year posttransplant is predictive of patient survival, especially in elderly recipients with normal SBP. Combined analysis of SBP and PP showed that high PP confers additional predictive information for patient survival beyond that derived from analysis of SBP alone. With regard to prediction of death-censored graft survival, the combination of high SBP and high PP showed the best correlation across all age groups.

[1]  M. Palta,et al.  The Association Between Renin-Angiotensin System Blockade and Long-term Outcomes in Renal Transplant Recipients: The Wisconsin Allograft Recipient Database (WisARD) , 2016, Transplantation.

[2]  Christine A. White,et al.  Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[3]  S. Solomon,et al.  BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. , 2014, Journal of the American Society of Nephrology : JASN.

[4]  G. Opelz,et al.  Renin-Angiotensin system blockers and cardiovascular death in kidney recipients. , 2014, Transplantation.

[5]  G. Opelz,et al.  Cardiovascular Death in Kidney Recipients Treated With Renin–Angiotensin System Blockers , 2013, Transplantation.

[6]  A. Dominiczak,et al.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. , 2013, Journal of hypertension.

[7]  G. L’italien,et al.  The External Validation of the Cardiovascular Risk Equation for Renal Transplant Recipients: Applications to BENEFIT and BENEFIT-EXT Trials , 2013, Transplantation.

[8]  I. Holme,et al.  A Cardiovascular Risk Calculator for Renal Transplant Recipients , 2012, Transplantation.

[9]  Mahboob Rahman,et al.  Hemodynamic correlates of proteinuria in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[10]  J. Kaski,et al.  Pulse pressure and progression of chronic kidney disease. , 2010, Journal of nephrology.

[11]  R. Schmieder,et al.  Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  P. Fesler,et al.  Early High Pulse Pressure is Associated With Graft Dysfunction and Predicts Poor Kidney Allograft Survival , 2009, Transplantation.

[13]  B. Pannier,et al.  Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality , 2008, Journal of hypertension.

[14]  M. Zeier,et al.  No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  G. Heinze,et al.  Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. , 2006, Journal of the American Society of Nephrology : JASN.

[16]  G. Opelz,et al.  Improved Long‐Term Outcomes After Renal Transplantation Associated with Blood Pressure Control , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Helmut Schulte,et al.  Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. , 2005, European heart journal.

[18]  M. Arias,et al.  Association Between Pulse Pressure and Cardiovascular Disease in Renal Transplant Patients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  I. Holme,et al.  Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post‐Hoc Subgroup Analyses of the ALERT Study , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  Roberto Pastor-Barriuso,et al.  Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure: An Evaluation of Their Joint Effect on Mortality , 2003, Annals of Internal Medicine.

[21]  C. Hengstenberg,et al.  Cardiovascular Risk Factors and Estimated Risk for CAD in a Randomized Trial Comparing Calcineurin Inhibitors in Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  B. Brenner,et al.  Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. , 2003, Archives of internal medicine.

[23]  M. Pfeffer,et al.  Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). , 2002, JAMA.

[24]  T. Risler,et al.  Antihypertensive treatment for kidney transplant recipients , 2002 .

[25]  R. Asmar,et al.  Reference values for clinic pulse pressure in a nonselected population. , 2001, American journal of hypertension.

[26]  Martin G. Larson,et al.  Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?: The Framingham Heart Study , 2001, Circulation.

[27]  B. Kasiske,et al.  Explained and unexplained ischemic heart disease risk after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[28]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[29]  M. Joffe,et al.  Blood pressure and the survival of renal allografts from living donors. , 2004, Journal of the American Society of Nephrology : JASN.

[30]  G. Opelz,et al.  Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. , 1998, Kidney international.